ReviewFrontiers in microbiology2020
Considerations for Phage Therapy Against
Review in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Smooth-to-rough morphotype switching, a mechanism of phage resistance inProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Combined bacteriophage and antibiotic therapy for refractory peritoneal dialysis-related peritonitis caused by Klebsiella pneumoniae.Nature communications · 2026Article
- Review
- Complete Genome Sequences of Four Mycobacteriophages Involved in Directed Evolution against UndisputedMicroorganisms · 2024Article
- Isolation and characterization of two novel bacteriophages against carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Article
- Article
- Experimental Studies of the Liposomal Form of Lytic Mycobacteriophage D29 for the Treatment of Tuberculosis Infection.Microorganisms · 2023Article
- Managing Patient and Clinician Expectations of Phage Therapy in the United Kingdom.Antibiotics (Basel, Switzerland) · 2023Article
- Phage Therapy for Nontuberculous Mycobacteria: Challenges and Opportunities.Pulmonary therapy · 2023Review
- Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections.Frontiers in microbiology · 2023Review
- Role of bacteriophage therapy for resistant infections in transplant recipients.Current opinion in organ transplantation · 2022Review
- Review
- A Review on Mycobacteriophages: From Classification to Applications.Pathogens (Basel, Switzerland) · 2022Review
- Beyond antibiotics: recent developments in the diagnosis and management of nontuberculous mycobacterial infection.Breathe (Sheffield, England) · 2022Review
- Article
- Comparative genome analysis reveals high-level drug resistance markers in a clinical isolate ofFrontiers in cellular and infection microbiology · 2022Article
- Insertion Mutation ofInfection and drug resistance · 2022Article
- Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus.Disease models & mechanisms · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a global increasing number of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.